Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife®

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 19 years old~* Defect size: 2 to 10 ㎠ on the unilateral knee cartilage (up to 4 ㎤ in volume)~* Defect: isolated ICRS (International Cartilage Repair Society) grade III or IV single defect chondral lesion on articular cartilage~* The joint space is maintained over 50% relative to baseline~* Patients that are able to walk without aid~* Patients that agree to abide by strict rehabilitation protocols and follow-up programs~* Patients who provide written consent to the participation of the clinical trial~Exclusion Criteria:~* Patients with inflammatory articular diseases such as rheumatoid arthritis or gouty arthritis~* Patients with arthritis associated with autoimmune disease~* Patients hypersensitive to bovine protein~* Patients with Haemophilia or markedly reduced immune function~* Patients hypersensitive to antibiotics such as gentamicin~* Patients with arterial bleeding and severe venous bleeding~* Patients with other diseases including tumors except for cartilaginous defects of joints~* Patients with a history of radiation treatment and chemotherapy within the past two years~* Patients who are pregnant, nursing a baby or likely to get pregnant~* Patients who participate in concurrent clinical trials or previous clinical trials within 30 days of administration~* Other cases where the investigator deems the patient ineligible for participation

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CartiLife (low-dose group) (Type: EXPERIMENTAL): Total defect volume in low-dose group is less than 2 ㎤. Low- and high-dose group are sequentially processed.
- CartiLife (high-dose group) (Type: EXPERIMENTAL): Total defect volume in High-dose group is 2 \~ 4 ㎤.

Based on this trial design, predict the completion outcome and termination type (if applicable).